The healthcare technology mergers and acquisitions landscape has transitioned into a regime of industrial maturity, moving decisively past the speculative pricing cycles of the post-pandemic era. During the height of the market peak, high-growth digital health platforms were valued primarily on projected revenue expansion, frequently disregarding long-term margin profiles or underlying product defensibility. This pricing paradigm has been replaced by a rigorous valuation disc